| Theravance, Inc. (THRX) - Financial and Strategic | | | | analysis of Theravance, Inc., including a detailed SWOT |
| Analysis Review | | | | analysis, and deliver this direct to you in pdf format |
| Theravance, Inc. (Theravance) is engaged in the | | | | within two business days (excluding weekends). |
| discovery, development and commercialization of new | | | | The profile contains critical company information |
| medicines. Its drug discovery efforts are based on its | | | | including*, |
| expertise in multivalency. Multivalency involves the | | | | - Business description – A detailed description of the |
| instantaneous attachment of a single molecule to | | | | company's operations and business divisions. |
| multiple binding sites on biological targets. It also | | | | - Corporate strategy – Analyst's summarization of |
| effectively partnered with leading global pharmaceutical | | | | the company's business strategy. |
| and Astellas Pcompanies such as GlaxoSmithKline | | | | - SWOT Analysis – A detailed analysis of the |
| harma to accelerate the development and | | | | company's strengths, weakness, opportunities and |
| commercialization of product candidates. The | | | | threats. |
| company makes substantial investments in | | | | - Company history – Progression of key events |
| multivalency and other technologies to maintain its | | | | associated with the company. |
| competitive advantages in the area of drug discovery. | | | | - Major products and services – A list of major |
| Theravance, Inc. Key Recent Developments | | | | products, services and brands of the company. |
| Apr 15, 2010: Theravance Begins Proof of Concept | | | | - Key competitors – A list of key competitors to the |
| TD-1211 Phase 2 Trial | | | | company. |
| Nov 30, 2009: FDA Provides Complete Response | | | | - Key employees – A list of the key executives of |
| Letter To Theravance For Telavancin | | | | the company. |
| Nov 30, 2009: EMEA Completes Validation Phase For | | | | - Executive biographies – A brief summary of the |
| Theravance's Telavancin MAA | | | | executives' employment history. |
| Nov 05, 2009: Theravance, Astellas Launch Vibativ In | | | | - Key operational heads – A list of personnel |
| US | | | | heading key departments/functions. |
| This comprehensive SWOT profile of Theravance, Inc. | | | | - Important locations and subsidiaries – A list and |
| provides you an in-depth strategic analysis of the | | | | contact details of key locations and subsidiaries of the |
| company's businesses and operations. The profile has | | | | company. |
| been compiled to bring to you a clear and an unbiased | | | | - Key manufacturing facilities – A list of key |
| view of the company's key strengths and | | | | manufacturing facilities of the company. |
| weaknesses and the potential opportunities and | | | | - Detailed financial ratios for the past five years – |
| threats. The profile helps you formulate strategies that | | | | The latest financial ratios derived from the annual |
| augment your business by enabling you to understand | | | | financial statements published by the company with 5 |
| your partners, customers and competitors better. | | | | years history. |
| This company report forms part of the ‘Profile on | | | | - Interim ratios for the last five interim periods – The |
| Demand' service, covering over 50,000 of the world's | | | | latest financial ratios derived from the quarterly |
| leading companies. Once purchased, the highly qualified | | | | semi-annual financial statements published by the |
| team of company analysts will comprehensively | | | | company for 5 interims history. |
| research and author a full financial and strategic | | | | |